We aimed to investigate the effect of berberine on adipose tissues, as well as its effect on renal injury in 3T3-L1 cells and spontaneously hypertensive rats. 3T3-L1 cells were cultured and treated with berberine (5-20 μM) from days 3 to 8. Berberine added to the cultured medium could significantly down-regulate transcription factors, including CCAAT/enhancer binding protein β, CCAAT/enhancer binding protein α, and peroxisome proliferator-activated receptor γ, and suppress peroxisome proliferator-activated receptor target genes, such as adipocyte fatty acid binding protein and fatty acid synthase, and inhibit 3T3-L1 fibroblast differentiation to adipocytes. Male spontaneously hypertensive rats received either 150 mg/day of berberine or saline orally for 8 weeks. Compared with the control, berberine-treated rats exhibited significant reductions in body weight gain (p<0.05), as well as retroperitoneal and mesenteric adipose tissues (p<0.05). Berberine-treated rats significantly decreased urinary albumin excretion, a marker of renal injury (p<0.05). Long-term treatment with berberine decreased the adipose tissues weight and attenuated renal injury in spontaneously hypertensive rats. Based on these results, berberine has an important role in regulating adipose tissues. These results suggest the protective effect of berberine on metabolic syndrome related diseases, such as renal injury.
Berberine, an isoquinoline alkaloid, is present in roots, stem bark and rhizomes of seven plant families [1] . Previous reports suggested that berberine has many health benefits, including protection against cardiovascular disease and other diseases [2a,b] . Recently, metabolic syndrome has become a global health concern that refers to a constellation of risk factors for cardiovascular disease. Cicero et al.'s [3] review focused on widely marketed nutraceuticals with clinically demonstrated effects on more than one component of metabolic syndrome, such as berberine and psyllium. Pérez-Rubio et al. [4] evaluated the effect of berberine administration on subjects with metabolic syndrome. Several studies reported that berberine attenuated 3T3-L1 adipocyte differentiation in vitro [5a, b] . Our previous report also demonstrated that berberine inhibited 3T3-L1 preadipocyte differentiation into adipocytes and attenuated oxidative stress in differentiated 3T3-L1 cells [6] ; however, evidence on transcription factors and peroxisome proliferator-activated receptor target genes in 3T3-L1 adipocytes after berberine treatment was insufficient. In a rodent study, the effect of berberine on adipose tissues was inadequate. Although spontaneously hypertensive rats (SHR) show the development of hypertension and oxidative stressrelated disease, such as kidney injury [7 a,b] , the effect of berberine on adipose tissues in SHR has not been documented. In the present study, we examined that the effect of berberine on adipose tissues in 3T3-L1 cells and SHR.
To confirm whether berberine inhibits 3T3-L1 cell differentiation via suppressing transcription factors, total RNA was purified from Day 8-differentiated 3T3-L1 cells and PCR was carried out. Berberine at 20 μM decreased CCAAT/enhancer binding protein beta (C/EBP β) mRNA at 10 expression significantly (16%, P <0.01) ( Figure 1b) , and berberine and 20 μM decreased C/EBP α (22 and 47%, respectively) ( Figure 1c ) and peroxisome proliferatoractivated receptor-gamma (PPAR γ) (22 and 55%, respectively) mRNA levels significantly in 3T3-L1 adipocytes (Figure 1d ). PPAR target genes, including fatty acid synthase (FAS) and adipocyte fatty acid binding protein (aP2), were evaluated by PCR. As expected, FAS and aP2 gene expressions were significantly increased (18 and 1,071%, respectively) in adipocytes, when compared with preadipocytes. Berberine at 10 and 20 μM markedly decreased aP2 gene expression (18 and 40%, respectively, P <0.001) in 3T3-L1 adipocytes in a dose-dependent manner (Figure 1e ). Berberine at 20 μM reduced FAS mRNA expression significantly (18%, P <0.01) in 3T3-L1 adipocytes ( Figure 1f ). The results indicate that berberine treatment suppressed PPARs target genes, which might be associated with the suppression of lipogenesis and adipogenesis.
The mean body weight of SHR given150 mg/day berberine (BBR) orally was lower than that of SHR given saline (control) at the end of the experiment. The mean starting body weight of BBR and control rats at the baseline before assignment to groups were 173±5 and 171±5 g, respectively; at the end of the 8-week study, the mean body weights were 338±12 g in BBR and 351±7 g in control (p=0.058). Figure 2 shows that the increased body weight of BBR was significantly lower than that of control (165±8 vs. 180±8g, respectively, p=0.012). Weekly food consumption and 24-h food intake in metabolic cages (11.8±0.9 vs. 12.1±1.1 g, respectively) were not changed between BBR and control. The blood pressure of BBR did not significant change compared with that of control (Table 1) . Visceral adipose tissue weights, such as epididymal, retroperitoneal and mesenteric adipose tissues, in BBR were decreased compared with the control (Figure 3a ). Brain, heart and kidney weights were not changed between BBR and control (Brain: 1.90±0.05 vs. 1.93±0.03 g., Heart, 1.31±0.09 vs. 1.39±0.02 g). Kidneys weight in NPC Natural Product Communications 2015 Vol. 10 No. 9 1543 -1546 Figure 1 : The effect of berberine on gene expression of transcription factors and PPAR target genes during 3T3-L1 cell differentiation. Transcription factors including CCAAT/enhancer-binding protein beta (C/EBP β), C/EBP α, and peroxisome proliferator-activated receptor gamma (PPAR γ), and PPAR target genes, such as adipocyte-specific acid binding protein (aP2) and fatty acid synthase (FAS) mRNA gene expression, were tested by the RT-PCR method using GAPDH as an internal control. Each bar represents the mean ± SEM, with n=3.
* P <0.05, ** P <0.01, *** P <0.001 vs. adipocyte group.
BBR were significantly smaller than that in control (2.43±0.13 vs. 2.57±0.07g, p<0.05).
On histological analysis, the fat size was smaller and cell numbers were increased in BBR compared with control rats (Figure 3b ). The level of dROM tended to be lower in BBR than in control (BBR: 305 ± 8, Control: 312 ±11Ucarr). The 24-h urine volume showed no significant difference between BBR and control (14.2±0.8 vs.15.3.±1.3 mL, respectively). The 24-h urinary albumin excretion in BBR was significantly attenuated compared with that in control ( Figure 4 ). Our study suggests that berberine could down-regulate transcription factors such as C/EBP β, C/EBP α, and PPAR γ, and inhibit 3T3-L1 fibroblast differentiation to adipocytes. We also observed body weight gain reduction due to decreased adipose tissues, retroperitoneal and mesenteric adipose tissues, in BBR rats for 8 weeks. Furthermore, BBR showed attenuated renal injury parameters, such as 24-h urinary albumin.
During the induction of differentiation, multiple transcription factors are involved in adipogenesis, such as C/EBP β, C/EBP α, and PPAR γ. C/EBP β is induced at the early stage of 3T3-L1 differentiation and is required for expression of the downstream transcription factors C/EBP α and PPAR γ [8] , key transcription factors in adipogenesis and lipogenesis [9] . In our study, the results demonstrated that berberine added from days 3 to 8 inhibited adipocyte differentiation and fat accumulation, and suppressed gene expression of C/EBP β and the downstream transcription factors PPAR γ and C/EBP α. PPAR γ target genes, such as aP2 and FAS mRNA expression, were also significantly reduced after berberine treatment. Our studies suggest that berberine could down-regulate transcription factors (i.e., C/EBP β, C/EBP α, and PPAR γ) and PPAR target genes (i.e., aP2 and FAS) and inhibit 3T3-L1 fibroblast differentiation to adipocytes.
There are many reports of beberine reducing body weight gain in rats given a high fat diet [10 a,b], and then failed to observe body weight reduction in streptozotosin-induced diabetic rats [11 a, b] . In relation to SHR, the effects of berberine on hypertension and endothelium-dependent contractions have been documented [12a,b] , but the effect on adipose tissues was not documented.
In our study, BBR showed significant reduction in body weight gain and visceral adipose tissues, such as retroperitoneal and mesenteric 
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Our previous report suggested that berberine suppressed the production of reactive oxygen species, as assessed by the NBT assay, in a concentration-dependent manner, using differentiated 3T3-L1 cells which are adipocytes [6] . Liu et al. [12a] suggest that berberine improves the endothelial function by inhibiting endoplasmic reticulum stress and subsequently scavenging reactive oxygen species in SHR carotid arteries. On analyzing the plasma levels of reactive oxygen metabolites, BBR showed a decreasing tendency, but this was not significant in this study. An improved endothelial function may not change plasma levels of oxidative states. SHR develop hypertension and a modest renal mass reduction resulting in significant histological renal injury [13a,b] . Guo et al. [12b] documented the anti-hypertensive and renoprotective effects of berberine in SHR. They concluded that berberine delayed the onset and attenuated the severity of hypertension, as well as ameliorating hypertension-induced renal damage.
Our data showed reduced renal injury without a change in blood pressure. This was confirmed by the heart weight showing no change between BBR and control. BBR showed attenuated renal injury without a reduction in blood pressure. In addition to hypertension, another factor could involve the attenuation of renal injury in SHR. Further study will be needed.
In conclusion, our in vitro studies suggested that berberine could down-regulate the transcription factors C/EBP β, C/EBP α, PPAR γ, and PPAR target genes (i.e., aP2 and FAS) and inhibit 3T3-L1 fibroblast differentiation to adipocytes. In the in vivo study, berberine treatment reduced body weight gain and decreased retroperitoneal and mesenteric adipose tissue weights in SHR. Berberine treatment attenuated the renal injury without attenuation of hypertension in SHR. Berberine has marked potential health benefits for the prevention of obesity and adipokine production, which underlies the pathophysiology of obesity in relation to metabolic syndrome, such as kidney injury. 
Experimental
Cell culture: Murine 3T3-L1 preadipocytes obtained from Health Science Research Resources Bank (Osaka, Japan) were grown on FALCON 6-well plates (New Jersey, USA) in a 5% CO 2 atmosphere at 37°C and maintained in low glucose Dulbecco's Modified Eagle's medium (DMEM, 1,000 mg D-glucose/L) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. The 2-day postconfluent 3T3-L1 cells (designated as Day 0) were incubated with 10% FBS/high glucose DMEM (HG-DMEM, 4,500 mg D-glucose/L) and antibiotics, 500 μM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 5 μg/mL insulin for 3 days (Days 0-2). Then, the cells were incubated for 2 days in 10% FBS/HG-DMEM with insulin (Days 3-4), and, thereafter incubated in 10% FBS/HG-DMEM that was changed once every 2 days (Days 5-8). Cells receiving berberine chloride were given 10% FBS/HG-DMEM and insulin containing a final concentration of 5, 10, and 20 μM of berberine in DMSO on Day 3 and then the medium was changed to only 10% FBS/HG-DMEM with berberine for the last 4 or 5 days (Day 8). Ret.
Mes. ) . All experiments in the present study conformed to Guidelines for the Care and Use of Laboratory Animals at Japan SLC, Inc. All rats were housed under controlled conditions of a constant temperature (22°C) and a light/dark cycle of 12 h with free access to food and water for one week. These rats at 6 weeks old were divided into 2 groups: one group of rats was orally administered 150 mg/kg body weight daily, and the other group was treated with an equal volume of saline as control. The blood pressure, body weight, and food-intake were recorded weekly in these rats. After 8 weeks, rats underwent 24-h collection using metabolic cages. At the end of treatment, rats were fasted overnight and anesthetized with isoflurane. Upon anesthesia, blood was collected from the vena cava and rats were sacrificed. These rat tissues were sampled after sacrifice.
Reverse transcription-polymerase chain reaction:
Blood parameters: Blood samples were obtained from the aorta of rats. The blood samples were centrifuged, and serum and plasma were frozen at -70°C for the subsequent measurement of blood parameters. The Diacron reactive oxygen metabolite test (d-ROM test) was performed (Diacron SPF, Grosseto, Italy) to analyze the plasma levels of reactive oxygen metabolites. The results of the dROM test are expressed in arbitrary units called "Carratelli units" (U. CARR), where 1 U. CARR corresponds to 0.08 mg/dL of H 2 O 2 .
Urine parameters: At 14 weeks old, each rat was placed in an individual metabolic cage to collect urine over 24 h, and urine samples were collected and frozen at -70°C for subsequent analysis.
In the metabolic cage, the urine volume, fecal volume, water intake, and diet intake were measured. The urine samples were used to calculate albumin excretion.
Histological analysis:
Adipose tissues from rats were stained with hematoxylin and eosin and examined by a light microscopy in a blinded fashion.
Statistical analysis:
In the in vitro study, all data were analyzed by one-way analysis of variance. Multiple group comparisons were made with least significant post hoc tests by SPSS 17.0. A significant difference was defined as a value of P < 0.05. The statistical significance of differences in mean values was assessed using Student's t-test. A p-value of < 0.05 was accepted as significant in the in vivo study.
